That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon,.
Today, the Centers for Medicare and Medicaid Services (CMS) released the results from the Medicare Drug Price Negotiation Program for Initial Price Applicability Year (IPAY) 2027 (press release)..
A 2024 Data Quality Framework (DQF) from the European Medicines Agency (EMA) aims to provide some guidance for drug manufacturers. Here is a summary of that document.
Factors to be considered when.
On September 19, 2025, an executive order increased the fee for new H-1B petitions from approximately $3500 to $100 000 per applicant. How is this policy likely to.
Ask.
Helpful tips from Jim Rohn.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for.
What drug characteristics lead to higher vs. lower prices in the US? A paper by Beinfeld et al. (2025) finds the answer using data from SSR Health.
Last week, CMS announced the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model. The program basically is a ‘most favored nation’ style reference pricing based on net.
